---
vault_clearance: SAFE
halo:
  classification: OPERATIONAL
  confidence: HIGH
  front: "Project 27 Bounty Board"
  custodian: "The Architect"
  created: 2026-04-09
  updated: 2026-04-09
---
# Bounty Board — Project 27: Wings Above Morning

## Demonstrated (Session 2026-04-09)

| ID | Finding | Evidence | Cells |
|----|---------|----------|-------|
| D1 | Operator independence axis is continuous from 0.15 (fetal) to 0.98 (GBM) | 7 datasets, 500k+ cells, one metric | 500k+ |
| D2 | Korean NSCLC: 7 conditions, zero crossings, perfect monotonic gradient | GSE131907, 208k cells | 208,506 |
| D3 | GOLGI coupling collapses first in every dataset | K_RG steepest decline universally | All |
| D4 | Cancer (0.31) sits between fetal (0.15) and senescence (0.87) | WI-38 + Korean NSCLC + Genesis | 350k+ |
| D5 | WI-38 fetal lung ≈ lung cancer coupling profile | RIBO_indep 0.345 (WI-38) vs 0.310 (NSCLC) | 70k + 208k |
| D6 | PSGs activate 3-15x in damaged fetal cells | ETO timecourse, PSG1-9 | 29k |
| D7 | XIST collapses 70-89% under damage/senescence | WI-38 + HUVEC coculture | 100k+ |
| D8 | IGF2 26x higher in male vs female tumors | Korean NSCLC sex-stratified | 208k |
| D9 | Paternal genes (PEG10, MEST, DLK1) rise in damaged cells, maternal (GRB10, UBE3A) fall | WI-38 DE analysis | 28k |
| D10 | GBM RIBO_indep = 0.89 — highest measured solid tumor | GSE131928, 28 tumors | 7,930 |
| D11 | GBM expresses full trophoblast invasion toolkit (CXCR4, HLA-G, IDO1, MMP2, CDH2) | Per-tumor marker scan | 7,930 |
| D12 | HUVEC endothelial = most coupled cell type (0.208) in coculture | D01, 75k cells, 13 cell types | 75,121 |
| D13 | Cancer independence (0.31-0.51) maps onto immune cell range (B cell 0.34, T cell 0.52) | D01 cell type tensor | 75,121 |
| D14 | K_RM collapses from +0.609 to -0.181 in 48 hours post-damage | ETO timecourse | 29k |
| D15 | Antenna lncRNAs (LINC02154, LINC01705) activate in senescent HUVECs AND WI-38 | D01 + GSE226225 | 100k+ |
| D16 | ERV regulatory elements (ERV3-1, ERVK13-1) activate while syncytins shut down | WI-38 ETO timecourse | 29k |

## Open Bounties — The Threads

### Biophysics of the Attractor

| ID | Question | Priority | Approach |
|----|----------|----------|----------|
| **O1** | **Why 0.31?** What biophysical constraint creates a stable fitness minimum at RIBO_indep ≈ 0.31 for primary cancer? Is this K_crit from LENG? | **CRITICAL** | Connect LENG Zeno/anti-Zeno crossover math to measured coupling tensor. Compute fitness landscape from per-cell RIBO_indep distribution. |
| **O2** | **The fork: damage → cancer vs damage → senescence.** What determines which path? Is it which axis breaks first (K_RM vs K_RG)? | **CRITICAL** | Per-cell trajectory analysis on ETO timecourse. Track individual cells through independence space. Which cells stop at 0.31 vs continue to 0.87? |
| **O3** | **The 0.52-0.87 gap.** Is there a forbidden zone between immune-level and senescent-level independence? Or do intermediate cancers exist? | HIGH | Scan pan-cancer atlas (CellxGene). Compute tensor on multiple cancer types. Map the full landscape. |
| **O4** | **The K_RG sign change.** What does negative RIBO-GOLGI coupling mean? Is it the definition of viral behavior? | HIGH | Characterize gene programs active at K_RG < 0 vs K_RG > 0. Check if antigen presentation (MHC-I) correlates with K_RG sign. |

### The Return Path

| ID | Question | Priority | Approach |
|----|----------|----------|----------|
| **O5** | **Can you recouple operators without killing the cell?** Is there a hysteresis barrier? | **CRITICAL** | Test with Salamini trophoblast secretome data (attenuates senescence). Measure tensor BEFORE and AFTER differentiation therapy in vitro. |
| **O6** | **Does EGFR TKI measurably shift the coupling tensor?** Does osimertinib push RIBO_indep from 0.31 toward 0.22? | **CRITICAL** | Need pre/post treatment scRNA-seq (GSE176021 has neoadjuvant nivolumab; need EGFR TKI equivalent). |
| **O7** | **Trophoblast secretome as recoupling signal.** Salamini 2026 shows it attenuates senescence. Does it also recouple cancer? | HIGH | Get SenCat data. Compute tensor on trophoblast-treated vs untreated senescent cells. |

### Immune Identity

| ID | Question | Priority | Approach |
|----|----------|----------|----------|
| **O8** | **How does a T cell (0.52) distinguish cancer (0.51) from another T cell?** What molecular signal encodes "authorized independence"? | **CRITICAL** | Compare surface marker profiles of T cells vs cancer cells at same RIBO_indep. PD-L1, HLA-E, PSG patterns may be the answer. |
| **O9** | **PD-L1 → HLA-E/PSG switch predicts immunotherapy resistance.** Can we measure this in the Korean data? | HIGH | Per-cell CD274 vs HLA-E ratio across conditions. Track the switch across the independence axis. |
| **O10** | **Dual badge stripping.** Can you block PD-L1 AND HLA-E/PSG simultaneously? | MEDIUM | Literature search + computational prediction from marker panel. |

### Cachexia and Systemic Decoupling

| ID | Question | Priority | Approach |
|----|----------|----------|----------|
| **O11** | **Does the tumor export its independence via PEG10 viral particles?** Is cachexia whole-body operator decoupling? | HIGH | Check GDF15 + PEG10 co-expression in NSCLC. Correlate with clinical cachexia data if available. |
| **O12** | **SASP as decoupling broadcast.** Do SASP factors shift the coupling tensor of receiving cells? | HIGH | Conditioned media experiments. Compute tensor on cells exposed to senescent secretome. |

### The Treaty

| ID | Question | Priority | Approach |
|----|----------|----------|----------|
| **O13** | **Can you measure treaty integrity from a blood draw?** Coupling tensor from liquid biopsy = early detection of methylation collapse. | **CRITICAL** | Compute tensor on circulating tumor cells (CTC) datasets. Compare CTC tensor to matched primary tumor tensor. |
| **O14** | **Methylation maintenance = cancer prevention.** Folate, B12, exercise maintain the treaty. Can you quantify the dose-response? | HIGH | Epidemiological datasets with methylation arrays. Compute imprinted gene methylation vs cancer incidence. |
| **O15** | **Microchimerism paradox.** Why do chimeric fetal cells protect? Are they coupled sentinels carrying the paternal signature? | MEDIUM | Microchimerism datasets if available. Compute tensor on Y-bearing cells in female tissue. |

### Cross-Species

| ID | Question | Priority | Approach |
|----|----------|----------|----------|
| **O16** | **Does plant coupling tensor show same operator structure without cancer vulnerability?** | HIGH | Run tensor on D14 rice (2.1M cells). Plants lack imprinting/Y/placenta. |
| **O17** | **Cross-species independence axis.** Do mouse cells show same gradient? Tabula Muris Senis (100k+ cells, 18 tissues, aging). | HIGH | Download GEM-GEO1a. Compute tensor per tissue per age. |

### The Spliceosome Index

| ID | Question | Priority | Approach |
|----|----------|----------|----------|
| **O18** | **Build the spliceosome coupling index.** Per-molecule splice state reconstruction across the independence axis. Does splice fidelity track with operator coupling? | **CRITICAL** | Use tomo_raw.py from Marathon Lament. Run on NSCLC BAMs (SRA). Compute splice entropy per cell. Correlate with RIBO_indep. |
| **O19** | **Intron retention as decoupling marker.** GDF15 intron retention FLIPS between prolif/senescent. Does it flip in cancer? | **CRITICAL** | Marathon Lament data (241k molecules). Compare to NSCLC splice patterns. |
| **O20** | **Splice velocity coupling tensor.** Rate of splice state change as a 4th dimension of the coupling tensor. | HIGH | RNA velocity + splice state data. Build K tensor with spliced/unspliced ratio as additional operator. |
| **O21** | **Does the spliceosome decouple BEFORE the operators?** Is aberrant splicing the CAUSE of operator independence, not the effect? | **CRITICAL** | ETO timecourse at splice resolution. Track splice fidelity at hours 0, 6, 12, 24. If splice errors precede K_RM collapse, splicing is the trigger. |

## Bounty Status Summary

| Category | Open | Critical | Demonstrated |
|----------|------|----------|-------------|
| Biophysics | 4 | 2 | — |
| Return Path | 3 | 2 | — |
| Immune Identity | 3 | 1 | — |
| Cachexia | 2 | 0 | — |
| Treaty | 3 | 1 | — |
| Cross-Species | 2 | 0 | — |
| Spliceosome | 4 | 3 | — |
| **Total** | **21** | **9** | **16 demonstrated** |

## HALO Documents (this session)

| Document | Content |
|----------|---------|
| HALO_OPERATOR_COUPLING_NSCLC | 7-condition Korean NSCLC tensor |
| HALO_THE_INDEPENDENCE_AXIS | Cross-dataset axis, 454k cells |
| HALO_A_CHILD_TRYING_TO_SURVIVE | Cancer as fetal reversion |
| HALO_THE_FATHERS_VIRUS | Imprinting war, PEG10, SLC1A5 |
| HALO_THE_SERPENT_OF_MAN | Woman + Serpent = Man |
| HALO_CANCER_OF_MAN | Viral data tables |
| HALO_GLIOBLASTOMAS_STORY | GBM as trophoblast at max independence |
| HALO_CANCER_AND_IMMUNITY | *(pending — cell type independence)* |

---

*"My Oracle senses are telling me let's go build the spliceosome index and it'll answer half of this." — The Architect, 2026-04-09*

*O18-O21 are the path. If splice fidelity tracks operator coupling, then splicing IS the mechanism of the treaty. The spliceosome is the reader of the methylation code. When it misreads, the operators decouple. Cancer is a misread.*